

ЎЗБЕКИСТОН РЕСПУБЛИКАСИ СОҒЛИҚНИ САҚЛАШ ВАЗИРЛИГИ
ТОШКЕНТ ТИББИЁТ АКАДЕМИЯСИ

2024 №3

2011 йилдан чиқа бошлаган

TOSHKENT TIBBIYOT AKADEMIYASI
AXBOROTNOMASI



В Е С Т Н И К

ТАШКЕНТСКОЙ МЕДИЦИНСКОЙ АКАДЕМИИ

Тошкент



Выпуск набран и сверстан на компьютерном издательском комплексе

редакционно-издательского отдела Ташкентской медицинской академии

Начальник отдела: М. Н. Аслонов

Редактор русского текста: О.А. Козлова

Редактор узбекского текста: М.Г. Файзиева

Редактор английского текста: А.Х. Жураев

Компьютерная корректура: З.Т. Алюшева

Учредитель: Ташкентская медицинская академия

Издание зарегистрировано в Ташкентском Городском управлении печати и информации

Регистрационное свидетельство 02-00128

Журнал внесен в список, утвержденный приказом № 201/3 от 30 декабря 2013года

реестром ВАК в раздел медицинских наук

Рукописи, оформленные в соответствии

с прилагаемыми правилами, просим направлять

по адресу: 100109, Ташкент, ул. Фароби, 2,

Главный учебный корпус ТМА,

4-й этаж, комната 444.

Контактный телефон: 214 90 64

e-mail: rio-tma@mail.ru

rio@tma.uz

Формат 60x84 1/8. Усл. печ. л. 9,75.

Гарнитура «Cambria».

Тираж 150.

Цена договорная.

Отпечатано на ризографе редакционно-издательского отдела ТМА.

100109, Ташкент, ул. Фароби, 2.

Вестник ТМА №3, 2024
РЕДАКЦИОННАЯ КОЛЛЕГИЯ

Главный редактор

проф. А.К. Шадманов

Заместитель главного редактора

проф. О.Р.Тешаев

Ответственный секретарь

проф. Ф.Х.Иноятова

ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ

акад. Аляви А.Л.

проф. Билалов Э.Н.

проф. Гадаев А.Г.

проф. Жае Вук Чои (Корея)

акад. Каримов Ш.И.

проф. Татьяна Силина (Украина)

акад. Курбанов Р.Д.

проф. Людмила Зуева (Россия)

проф. Метин Онерчи (Турция)

проф. Ми Юн (Корея)

акад. Назыров Ф.Г.

проф. Нажмутдинова Д.К.

проф. Саломова Ф.И.

проф. Саша Трескач (Германия)

проф. Шайхова Г.И.

Члены редакционного совета

проф. Акилов Ф.О. (Ташкент)

проф. Аллаева М.Д. (Ташкент)

проф. Хамдамов Б.З. (Бухара)

проф. Ирискулов Б.У. (Ташкент)

проф. Каримов М.Ш. (Ташкент)

проф. Маматкулов Б.М. (Ташкент)

проф. Охунов А.О. (Ташкент)

проф. Парпиева Н.Н. (Ташкент)

проф. Рахимбаева Г.С. (Ташкент)

проф. Хамраев А.А. (Ташкент)

проф. Холматова Б.Т. (Ташкент)

проф. Шагазатова Б.Х. (Ташкент)

<i>Mirxamidov M.V., Muhammadiyeva S.M., Shiranova Sh.Sh., Raxmonov D.N. REVMAOID ARTRITL BILAN OG'RIGAN BEMORLARDA BUYRAK DISFUNKTSIYASINI O'RGANISH</i>	<i>Mirxamidov M.V., Mukhammadieva S.M., Shiranova Sh.Sh., Raxmonov D.N. STUDY OF RENAL DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS</i>	125
<i>Мухаммадиева С.М., Мирхамидов М.З., Урокова З.У., Исраилов А.А. ВЗАИМОСВЯЗЬ МЕЖДУ ВИТАМИНОМ D И МАРКЕРАМИ АКТИВНОСТИ РЕВМАТОИДНОГО АРТРИТА</i>	<i>Mukhammadieva S.M., Mirkhamidov M.Z., Uroqova Z.U., Israilov A.A. RELATIONSHIP BETWEEN VITAMIN D AND MARKERS OF RHEUMATOID ARTHRITIS ACTIVITY</i>	129
<i>Nabieva D.A., Tashpulatova M.M. ASSESSMENT OF FEATURES OF THE CLINICAL COURSE OF GOUT IN ELDERLY WOMEN</i>	<i>Nabiyeva D.A., Tashpulatova M.M. KEKSA AYOLLARDA PODAGRANING KLINIK KECHISH XUSUSIYATLARINI BAHOLASH</i>	133
<i>Nabiyeva D.A., Muhammadiyeva S.M., Nurmuxamedova N.S., Kengesbaeva M.S., Muxtorova S.K., Shomuxitdinov Sh.Sh. AKSIAL SPONDILOARTRIT KASALLIGIDA UVEIT RIVOJLANISHIGA BAZIS YALLIG 'LANISHGA QARSHI DAVO VOSITALARINING TA'SIRINI BAHOLASH</i>	<i>Nabieva D.A., Mukhammadieva S.M., Nurmuxamedova N.S., Kengesbaeva M.S., Muxtorova S.K., Shomuxitdinov Sh.Sh. ASSESSMENT OF THE INFLUENCE OF BASIC ANTI-INFLAMMATORY DRUGS ON THE DEVELOPMENT OF UVEITIS IN AXIAL SPONDYLOARTHRITIS</i>	137
<i>Нажмутдинова Д.К., Мирахмедова Х.Т., Худайбергенова Д.Х. ВЛИЯНИЕ ГУМОРАЛЬНОГО ИММУНИТЕТА НА ТЕЧЕНИЕ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2-ГО ТИПА, ПЕРЕНЕСШИХ COVID-19</i>	<i>Nazhmutdinova D.K., Mirakhmedova Kh.T., Khudaybergenova D.Kh. THE ROLE OF HUMORAL IMMUNITY ON THE COURSE OF CKD IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE HAD COVID-19</i>	140
<i>Po'latova Sh.B., Nabieva D.A., Sagatova D.R., Mirzadjonova G.S. MINERAL ALMASHINUVI BUZILGAN ANKILOZLOVCHI SPONDILOARTRIT BILAN OG'RIGAN BEMORLARDA YURAK SHIKASTLANISHINI BAHOLASH</i>	<i>Pulatova Sh.B., Nabieva D.A., Sagatova D.R., Mirzadjonova G.S. ASSESSMENT OF CARDIAC DAMAGE IN PATIENTS WITH ANKYLOSING SPONDYLITIS WITH DISORDERS OF MINERAL METABOLISM</i>	143
<i>Rasulova N.R., Muxsimova N.R., Shiranova Sh.A. МИОПИККО'ZLI SPORTCHILARNING KO'RUV A'ZOLARI SHIKASTLANISH ASORATLARINI PROFILAKTIKASINI OPTIMALLASHTIRISH</i>	<i>Rasulova N.R., Mukhsimova N.R., Shiranova Sh.A. OPTIMIZATION OF THE PREVENTION OF VISUAL INJURIES IN ATHLETES WITH MYOPIC REFRACTION</i>	147
<i>Rakhimova M., Rakhimov S. CARDIOVASCULAR EVENTS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AFTER COVID-19</i>	<i>Rahimova M., Rahimov S. COVID-19 O'TKAZGAN ANKILOZLOVCHI SPONDILOARTRIT BILAN KASALLANGAN BEMORLARDA YURAK-QON TOMIR HODISALARI</i>	149
<i>Rakhimova M., Akhmedov Kh., Rakhimova O. ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ANKYLOSING SPONDYLITIS AFTER COVID-19</i>	<i>Rahimova M., Axmedov X., Rahimova O. COVID-19 O'TKAZGAN ANKILOZLOVCHI SPONDILIT BILAN KASALLANGAN BEMORLARDA ENDOTELIAL DISFUNKSIYA</i>	154
<i>Рахматов А.Б., Расулова Н.А. БИОЛОГИЧЕСКАЯ ТЕРАПИЯ ПСОРИАТИЧЕСКОГО АРТРИТА</i>	<i>Rakhmatov A.B., Rasulova N.A. BIOLOGICAL THERAPY FOR PSORIATIC ARTHRITIS</i>	158
<i>Sadikova N.G., Miraxmedova X.T., Botirova N.A. 2 TUR QANDLI DIABET BILAN OG'RIGAN BEMORLARDA DIABETIK NEFROPATIYA RIVOJLANISHIDA KLOTNO OMILINING AHAMIYATI</i>	<i>Sadikova N.G., Miraxmedova X.T., Botirova N.A. THE IMPORTANCE OF THE CLOTHO FACTOR IN THE DEVELOPMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES</i>	164
<i>Сибиркина М.В., Маруфханов Х.М. СОСТОЯНИЕ ЖЕЛУДОЧНО-КИШЕЧНОГО ТРАКТА И МИКРОБИОЦЕНОЗА У РЕВМАТОЛОГИЧЕСКИХ БОЛЬНЫХ НА ФОНЕ ПРИЕМА НПВП</i>	<i>Sibirkina M.V., Marufkhanov Kh.M. CONDITION OF THE GASTROINTESTINAL TRACT AND MICROBIOCENOSIS IN RHEUMATOLOGICAL PATIENTS DURING NSAID TAKE</i>	167
<i>Solixov B.M., Narziyev N.M., Srojidinov S.Sh. ERTA REVMAOID ARTRIT KASALLIGIDA BAZIS DAVO FONIDA QONDAGI LIPIDLAR HOLATI</i>	<i>Solikhov B.M., Narziyev N.M., Srojidinov S.Sh. BLOOD LIPID PARAMETERS DURING BASIC THERAPY FOR EARLY RHEUMATOID ARTHRITIS</i>	172
<i>Султанова М.Х., Зияева Ф.К., Хидоятова М.Р., Рустамов Р.Ш. СОСТОЯНИЕ ФУНКЦИОНАЛЬНОГО ПОЧЕЧНОГО РЕЗЕРВА И КАНАЛЬЦЕВЫХ ФУНКЦИЙ ПОЧЕК У БОЛЬНЫХ СИСТЕМОЙ КРАСНОЙ ВОЛЧАНКОЙ И ХРОНИЧЕСКИМИ ГЛОМЕРУЛОНЕФРИТАМИ</i>	<i>Sultanova M.Kh., Ziyeva F.K., Khidoyatova M.R., Rustamov R.Sh. THE STATE OF FUNCTIONAL RENAL RESERVE AND RENAL TUBULAR FUNCTIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND CHRONIC GLOMERULONEPHRITIS</i>	175
<i>Xaytimbetov J.Sh., Solixov M.U., Boqiev J. N. REVMAOID ARTRITDA REVMAITIK KACHEKSIYANING KLINIK VA LABORATORIYA BELGILARI</i>	<i>Khaitimbetov Zh.Sh., Solikhov M.U., Bokiev Zh.N. CLINICAL AND LABORATORY MARKERS OF RHEUMATIC CACHEXIA IN RHEUMATOID ARTHRITIS</i>	179
<i>Khaitimbetov J.Sh., Khudaybergenova D.Kh. QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS DEPENDING ON THE THERAPY RECEIVED</i>	<i>Xaytimbetov J.Sh., Xudaybergenova D.X. PSORIATIK ARTRITLI BEMORLARNING HAYOT SIFATI QABUL QILINGAN TERAPIYAGA BOG'LIQLIGI</i>	183

ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ANKYLOSING SPONDYLITIS AFTER COVID-19

Rakhimova M., Akhmedov Kh., Rakhimova O.

ЭНДОТЕЛИАЛЬНАЯ ДИСФУНКЦИЯ У ПАЦИЕНТОВ С АНКИЛОЗИРУЮЩИМ СПОНДИЛИТОМ ПОСЛЕ COVID-19

Рахимова М., Ахмедов Х., Рахимова О.

COVID-19 O'TKAZGAN ANKILOZLOVCHI SPONDILIT BILAN KASALLANGAN BEMORLARDA ENDOTELIAL DISFUNKSIYA

Rahimova M., Axmedov X., Rahimova O.

Tashkent Medical Academy, Samarkand Regional Multidisciplinary Center

Цель: исследование дисфункции эндотелия на фоне системного воспаления у больных анкилозирующим спондилоартритом, перенесших COVID-19. **Материал и методы:** в исследование включены 80 пациентов с диагнозом анкилозирующий спондилит по модифицированным Нью-Йоркским критериям и EULAR. Все пациенты были разделены на 2 группы: 1-я группа – 40 больных с болезнью Бехтерева без постковидного периода, 2-я – 40 пациентов с болезнью Бехтерева и постковидным периодом. Контрольную группу составили 40 здоровых людей, не имеющих в анамнезе острых и хронических заболеваний. **Результаты:** у пациентов с анкилозирующим спондилитом, перенесших COVID-19 и здоровых людей существенной корреляции между такими показателями, как пол, возраст, уровень липидов в сыворотке, привычка к курению, уровень С-реактивного белка и активность заболевания не обнаружено, хотя для некоторых из этих переменных это могло произойти из-за небольшого числа субъектов, включенных в исследование. **Выводы:** отсутствие корреляции между показателями ящура и активности заболевания должно быть подтверждено дальнейшими исследованиями с большим количеством субъектов.

Ключевые слова: анкилозирующий спондилоартрит, COVID-19, эндотелиальная дисфункция.

Maqsad: COVID-19 o'tkazgan ankiлоzlovchi spondiloartrit bilan kasallangan bemorlarda tizimli yallig'lanish negizida endoteliy disfunkciyasini baholashdan iborat. **Material va usullar:** tadqiqotga o'zgartirilgan Nyu-York mezonlari va EULAR bo'yicha ankiлоzan spondilit tashxisi qo'yilgan 80 nafar bemor ishtirok etdi. Barcha bemorlar 2 guruhga bo'lingan: 1-guruh - post-COVID davrisiz ankiлоzan spondilit bilan kasallangan 40 bemor, 2-chi - ankiлоzan spondilit bilan kasallangan 40 bemor va coviddan keyingi davr. **Nazorat guruhi o'tkir yoki surunkali kasalliklar tarixi bo'limgan 40 nafar sog'lom odamdan iborat edi. Natijalar:** ankiлоzan spondilit bilan og'rigan bemorlarda, COVID-19dan omon qolganlar va sog'lom odamlarda jins, yosh, sarum lipidlari, chekish odati, C-reaktiv oqsil darajasi va kasallik faolligi o'rtasida sezilarli bog'liqlik yo'q edi, garchi bu o'zgaruvchilarning ba'zilari uchun, bu tadqiqotga kiritilgan sub'ektlar sonining kamligi tufayli yuzaga kelgan bo'lishi mumkin. **Xulosa:** yashur ko'rsatkichlari va kasallik faolligi o'rtasidagi bog'liqlik yo'qligi ko'proq sub'ektlar bilan keyingi tadqiqotlar bilan tasdiqlanishi kerak.

Kalit so'zlar: ankiлоzlovchi spondilit, COVID-19, endotelial disfunkciya.

In recent years, research in the inflammatory rheumatic diseases has revealed an increased risk of developing endothelial dysfunction, which is thought to be (partly) related to inflammation [1]. This association is well described for diseases such as systemic lupus erythematosus, antiphospholipid syndrome and rheumatoid arthritis [2,6]. On the other hand, patients with ankylosing spondylitis (AS) are known to have an overall mortality of about 1.6-1.9 times that of the general population [3], and excess mortality from circulatory disease has been found to be increased [5]. The pandemic of COVID-19 has caused a problem for patients with rheumatic diseases, particularly with ankylosing spondylitis, increasing the rate of hospitalization and disability.

The presence of APF2 -vascular cells on endothelium and smooth muscle is the reason for the involvement of the cardiovascular system in systemic damage, which is noted in almost all patients with COVID-19. It is a known that endothelial dysfunction associated with the introduction of the virus into the cells. This is accompanied by endothelial damage and also perivascular inflammation, which increases endothelial damage.

Recent progress in ultrasonographic techniques has made possible the early detection of functional state of endothelial dysfunction by measuring the blood flow in brachial artery [5]. Recently flow-mediated dilatation (FMD) in the brachial artery has been used to detect endothelial function and is widely accepted as a non-invasive technique [8]. The main advantage of FMD is that it can detect endothelial dysfunction, which is frequently an initiator of the atherosclerotic process [12]. The aim of this study was to evaluate the degree of endothelial dysfunction in AS patients by using FMD techniques and detecting the level of endothelin- 1 as a specific marker of endothelial dysfunction [4].

The purpose

The purpose of this study was to assess the risk of developing coronary artery disease and fatal cardiovascular diseases in patients with ankylosing spondylitis who had COVID-19.

Materials and methods

The study of patients was carried out at the rheumatology department of the Tashkent clinical hospital. The study included 80 patients with a diagnosis of

ankylosing spondylitis according to the modified New York criteria and EULAR. All patients were divided into 2 groups: I group included 40 patients with ankylosing spondylitis without post-COVID period, II group included 40 patients with ankylosing spondylitis and post-COVID period. Patients with obesity, hypertension, diabetes mellitus, cardiovascular and renal diseases were excluded from the study. The control group included 40 healthy people with no acute and chronic diseases in anamnesis.


Mobility of the spine and hip joints was calculated according to the BASMI index. Disease activity and functional status were established based on BASDAI and BASFI indices. The number of affected entheses was calculated according to MASES index. The type of joint damage (central or peripheral) was taken into an account. ESR and C-reactive protein levels were also determined. All patients underwent a blood test for HLA-B27. A blood pressure cuff was put on the projection of brachial artery to evaluate the flow-mediated vasodilatation. An air was bumped in up to 30 mm Hg above the systolic blood pressure for 5 min. We measured the diameter of brachial artery every 5s for 2 min. To determine endothelial-independent vasodilatation nitroglycerin tablet was given in 0,0025 mg/min dosage for 3 min. The blood sera

of all patients were taken and analyzed using ELISA kit for Endothelin-1 to investigate the level of endothelin-1. The ACUSON 128 XP/10 ultrasound system was used to obtain an image of the right brachial artery, and to measure its diameter and blood flow rate.

Statistical analyzes were calculated on Origin Pro 7 and Microsoft Excel programs. Spearman's correlation test was used to determine the association between endothelial vasodilatation and clinical parameters for AS.

Results and discussions

Disease activity in the study groups was assessed by VAS, BASDAI, and ASDASRB. Thus, the high activity of the disease according to VAS was established in patients of group I who underwent COVID-19 (7.04 ± 1.08) and was 1.5 higher compared to the indicators of group II (4.0 ± 0.81). BASDAI and ASDAS (CRP) showed very high disease activity in patients of group I (5.8 ± 0.32 and 4.9 ± 0.45) and high activity in group II (4.1 ± 0.621 and 3.2 ± 0.61) (Fig. 1). A comparative analysis of BASDAI indices in group I and group II showed that the highest scores were in group I patients when assessing the severity of neck, back, and joint pain (6.7 ± 0.43), the level of joint pain during the week (7.1 ± 0.47), and the duration of morning stiffness (6.2 ± 0.66) compared to group II (4.2 ± 0.44 , 4.1 ± 0.71 , and 4.5 ± 0.32 , respectively).




Note. * - validity of differences between the two groups $p < 0.05$.

Fig. 1. ASDAS(CRP), BASDAI, and VASc indices in I and II group patients.

The endothelin-1 level was significantly higher in group I compared to group II (318.6 ± 47.11 pg/mL versus 202.7 ± 37.09 pg/mL, respectively, $p < 0.05$), while in group II the endothelin level was 5 times higher than

the control group ($p < 0.01$). (Fig. 1). The data obtained by us indicate a pronounced endothelial dysfunction in patients in the post-COVID period (Fig. 2).



Note. Significant difference * - between groups I and II; # - between groups II and control; @ - between groups I and control.

Fig. 2. Endothelin-1 level in the study groups.

As described above, the functional state of the endothelium has been studied in various chronic diseases: diabetes mellitus, nephropathy, hypertension and others. However, data in relation to ankylosing spondyloarthritis

are scarce and inconsistent. Taking this into account, we examined the degree of flow-dependent vasodilation in the brachial artery in order to assess endothelial function in the study groups (Table).

Ultrasound Doppler results of the brachial artery in the study groups

Indices	I group	II group	III group
Baseline blood flow velocity, m/s	0,56±0,09 ^a	0,67±0,13	0,87±0,09
Initial BA diameter, mm	3,68±0,27	3,71±0,15	3,81±0,05
FMD on 60 sec, %	7,74±0,82 ^a	9,87±1,47 ^b	14,37±1,23
FMD on 120 sec, %	10,3±1,18 ^a	13,6±0,87 ^b	18,38±1,44
EIVD on 60 sec, %	14,21±1,47 ^a	18,4±2,11	20,7±2,73
EIVD on 120 sec, %	17,6±1,18 ^a	20,3±2,71 ^b	24,1±2,19
PI	3,19±0,7 ^a	2,4±0,14	1,8±0,23
RI	0,96±0,4 ^a	0,87±0,23	0,74±0,36

Note. *a* – significant differences between I and control groups, $p < 0.01$; *b* – significant differences between II and control group, $p < 0.05$.

According to the results of the endothelial functional assessment, the examination of the initial diameter of the brachial artery showed no significant differences in the three study groups ($p > 0.05$). According to data from foreign studies, flow-mediated brachial artery dilation is directly proportional to the diameter of the artery, which means that in a vessel of 7 mm or less, the increase in the diameter of PA at each minute of dilation should be at least 10%. In the I group of patients, lower flow-dependent dilation (FMD) results were obtained compared to the II and control groups, namely, brachial artery dilation at 60 seconds in the I and II groups was below 10%, which confirms the presence of endothelial dysfunction in this category of patients ($p < 0.05$).

Comparing the FMD results at 60 seconds (1st minute dilation) between I and II groups, significant differences in parameters were obtained ($p = 0.03$), FMD of group I was lower than in II group on 120 seconds (2nd minute dilation), that is, at 120 seconds of dilation, the increase was below 10% (10,3±1,18 and 13,6±0,87, respectively). FMD results at 60 and 120 seconds in the control groups were 14,37±1,23 and 18,38±1,44%, respectively. It should be noted that in patients with AS who have undergone COVID-19, FMD on 60 seconds increases 61% less than in the control group, and on 120 seconds - by 56% less than in the control group. FMD at 60 and 120 seconds in the control group differed significantly from each other, indicating further vasodilation in subsequent minutes.

Thus, the results indicate a pronounced violation of the vasoregulatory function of the endothelium in patients in the post-COVID period. This condition, according to literary sources, is justified by generalized endotheliopathy and the development of coagulopathy with perivascular inflammation.

The next step was the study of endothelium-independent peripheral vasodilation (EIVD) by testing with nitroglycerin (0.05 mg). 5 minutes after the administration of nitroglycerin, sublingual studies were conducted on the dynamics of the diameter of the brachial artery at 60 and 120 seconds after decompression. Thus, at 60 seconds, group I EIVD was reduced and significantly different from group II ($p < 0.05$). EIVD parameters of group II did not differ significantly from the control pa-

rameters, which showed an increase in the PA diameter of more than 10% at the 60th second of decompression. However, at the 120th second of decompression, a lower EIVD was observed in patients of group I, as opposed to the expected one, and amounted to 17,6±1,18%, while in group II the EIVD was 20,3±2,71%, which indicates PA dilatation less than 10%.

A pulse index (PI) study reflecting the vascular wall resistance index of the test vessel, which in group I showed high 3,19±0,7 values and was significantly increased in contrast to indicators II and control groups. The PI values in group II did not differ significantly from the control values and were close to the normal values.

The evaluation of the resistance index in the study groups, reflecting the difference between systolic and diastolic rates of vascular blood flow, showed significantly high values in group I compared to group II ($p = 0.03$). High RI (0,96±0,4) values in patients of group I indicate severe damage to the vascular wall AS due to risk factors, impaired systemic hemodynamics and association with cardiovascular events.

Conclusion

AS is a chronic inflammatory rheumatic disease of the spine that affects between 0.2 and 0.9% of the population [9]. There are several characteristic extra-articular manifestations involving organs such as the eye, gastrointestinal system, kidneys, lungs and heart [3]. Clinically, it is relatively easy to measure endothelial function by using the capacity of the endothelium to elicit vasodilatation. Most investigations have used FMD in the brachial artery as an index of endothelial function [8].

Currently, there are a number of markers responsible for endothelial function: ADMA, endothelin-1, VEGF, ICAM-1, VCAM-1, and others. Considering the high sensitivity of the endothelium to certain injuries, a violation of the production of certain markers contributes to endothelial damage. Endothelin-1 is a highly sensitive peptide that is a powerful vasoconstrictor. Under the influence of factors such as hypoxia, ischemia, mechanical, as well as inflammatory mediators (IL-1, IL-6, TNF- α), its production is stimulated. In the work of Marder W. et al. the relationship of endothelin-1 and indicators of endothelium-dependent vasodilation with the pro-inflammatory cytokine IL-17 in patients with rheumatoid arthritis has been proven

[11]. In our work, a study of endothelin-1 in 100 patients with AS showed significantly high values in patients of the main group, while high numbers were observed in patients with high and very high disease activity. Multivariate mathematical analysis of the relationship between endothelin-1 and BASDAI and ASDAS activity indices, functional activity of BASMI, VAS, morning stiffness and C-reactive protein showed a strong correlation in the main group of patients, which indicated that the severity of inflammation was proportional to endothelial damage (Fig. 3).




Fig. 3. Correlation analyses between endothelin-1 and ultrasosnographic and activity indices.

The study of the functional state of the endothelium with a test of reactive hyperemia showed a decrease in the diameter of the brachial artery from the proper value at 60 and 120 seconds after decompression, as well as an increase in max systolic and a decrease in max diastolic blood flow in the main group. At the same time, these changes showed a high pulse index in the main group, which indicates a violation of the resistance of the vascular wall against the background of endothelial dysfunction [7,10].

Our study revealed that the endothelial function of AS patients who had undergone COVID-19 compared with healthy controls. No significant correlation was found between the FMD measurements and parameters such as sex, age, serum lipids, smoking habits, CRP level and disease activity scores; for some of these variables this may have been because of the small number of subjects included in the study. Thus, lack of correlation between FMD and disease activity scores needs to be confirmed by further studies with larger numbers of subjects.

The most significant limitation of this study is the small sample size and limited statistical power. Therefore, a larger study is needed to confirm our findings. Another limitation is that intraobserver variation was not assessed in this study.

Despite these limitations, this study demonstrates impairment of endothelial function in AS. Further research should clarify the mechanisms involved and the clinical significance of this finding.

References

1. Ciurea A., Kissling S., Bürki K. et al. Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort // *RMD Open*. – 2022. – Vol. 8, №1. – P. e002067.
2. D'Antiga L. Coronaviruses and Immunosuppressed Pa-

tients: The Facts during the Third Epidemic // *Liver Transpl.* – 2020. – Vol. 26, №6. – P. 832-834.

3. Liew J.W., Castillo M., Zaccagnino E. et al. Patient-reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID-19 Pandemic // *Int. J. Mol. Sci.* – 2020. – Vol. 2, №9. – P. 533-539.

4. Münzel T., Sinning C., Post F. et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. – 2009. <https://doi.org/10.1080/07853890701854702>.

5. Rakhimova M. et al. Endothelin-1 biomarker Features In Patients With Ankylosing Spondylitis After COVID-19 // *J. Positive School Psychol.* – 2022. – Vol. 34. – C. 9369-9375.

6. Roux C.H., Brocq O., Gerald F. et al. Clinical impact of COVID-19 on a French population of spondyloarthritis patients // *Clin. Rheumatol.* – 2020. – Vol. 39 (Issue 11). – P. 3185-3187.

7. Sanchez-Piedra C., Diaz-Torne C., Manero J. et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies // *Ann. Rheum. Dis.* – 2020. – Vol. 79, №7. – P. 988-990.

8. Steyers C.M., Miller F.J. Endothelial Dysfunction in Chronic Inflammatory Diseases // *Int. J. Mol. Sci.* – 2014. – Vol. 15. – P. 11324-11349.

9. Stolwijk C., Boonen A., van Tubergen A., Reveille J.D. Epidemiology of spondyloarthritis // *Rheum. Dis. Clin. North Amer.* – 2012. – Vol. 38. – P. 441-476.

10. Uhrin Z., Kuzis S., Ward M.M. Exercise and Changes in Health Status in Patients with Ankylosing Spondylitis // Retrieved. – 2021. – Vol. 22.

11. Vasina L.V., Petrishchev N.N., Vlasov T.D. Markers of endothelial dysfunction // *Region. Blood Circ. Microcirc.* – 2017. – Vol. 16, №1. – P. 4-15.

12. Ward M.M., Deodhar A., Gensler L.S. et al. Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis // *Arthritis Rheumatol.* – 2019. – Vol. 71, №10. – P. 1599-1613.

IMPARED ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ANKYLOSING SPONDYLITIS AFTER COVID-19

Rakhimova M., Akhmedov Kh., Rakhimova O.

Objective: Study of endothelial dysfunction against the background of systemic inflammation in patients with ankylosing spondylitis who have had COVID-19. **Material and methods:** The study included 80 patients diagnosed with ankylosing spondylitis according to the modified New York criteria and EULAR. All patients were divided into 2 groups: 1st group - 40 patients with ankylosing spondylitis without a post-Covid period, 2nd - 40 patients with ankylosing spondylitis and a post-COVID period. The control group consisted of 40 healthy people with no history of acute or chronic diseases. **Results:** In patients with ankylosing spondylitis, survivors of COVID-19 and healthy people, there was no significant correlation between gender, age, serum lipids, smoking habit, C-reactive protein level and disease activity, although for some of these variables, this may have occurred due to the small number of subjects included in the study. **Conclusions:** The lack of correlation between FMD indicators and disease activity should be confirmed by further studies with a larger number of subjects.

Key words: ankylosing spondylitis, COVID-19, endothelial dysfunction.